TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Step length in dual-task walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait speed in dual-task walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Regimen-Limiting Toxicities (RLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Phase 1 Participants With Efficacy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weight prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of inflammatory markers in plasma and sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comparison of basal and tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change in Lumbar Spine Areal BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose response to an oral glucose load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UPDRS part 3 (motor score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response (SVR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in modified Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in post-training knowledge about cancer
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical Attachment Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of Alveolar height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants having no symptomatic intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of refractive error and convergence insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between refractive error and reading ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of correction of refractive error on reading ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7 tesla MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of norepinephrine reuptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of ritonavir-boosted indinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of COVID-19+ PCR Patients in Self-quarantine Who Are Hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: Number of Health Care Workers Testing Positive at 2 Months
Endpoint domain: Adverse events/effects
Primary endpoint: number of transferred embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The rate of clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of sensory gating deficits in event related potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of participants alive at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Isolation of volatile Organic Compounds to breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary renin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acid-fast bacilli (AFB) culture negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Therapy completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of persistent alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Best-Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of AZD0837 and AR-H067637XX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual-Related Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bioverified Point-prevalence Abstinence at 27 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Event and Serious Adverse Event Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Weaving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Morphine Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SKAMP deportment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of patients with HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Shared Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater against the A/H5N8 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of eosinophils expressing a4b7 integrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Repigmentation of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency and types of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Capillary refill time response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural and Clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial flora in the intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cut off value of optical signal - antigen A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cut off value of optical signal - antigen B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cut off value of optical signal - antigen D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cut off value of optical signal - negative control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of concordance of the blood group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving LDL-C target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AVF patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Electrophysiological attributes related to suicide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: symptomatic convergence insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flanker Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Raven's matrices test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sternberg digit memory task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Paraoxonase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical cure at Early Clinical Response (ECR) visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: cfDNA conversion rate in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper Extremity Fugyl-Meyer Score (UEFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inter-hemispheric Inhibition (IHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of OPSCC
Endpoint domain: Mortality/survival
Primary endpoint: Arousal threshold (%eupnea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with prostate cancer detected
Endpoint domain: Mortality/survival
Primary endpoint: HPV-6 Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV-11 Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV-16 Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV-18 Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change in Symptoms and Signs of Oral Lichen Planus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in remembering steps of functional tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in migraine headache severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Plasma nicotine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Training-induced changes in emotion related processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in violent behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depressive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective well being under neuroleptic medication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of necessary neuroleptic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Service Engagement Scale (SES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appointment Attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological profile of lower respiratory tract specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Microbiological profile of urine specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Microbiological profile of serum specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: peritoneal metastasis rate
Endpoint domain: Mortality/survival
Primary endpoint: differential AAT index (∆RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Readiness for the Procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical features of human genetic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Natural history of human genetic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ranked Adjusted 2-Component Composite Variable Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss
Endpoint domain: Mortality/survival
Primary endpoint: Reliability of the sentinel lymph node technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Standing Vertigo Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodyweight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Quality of Life (EQ-5D-5L Index)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Continuous, 12-lead, Holter electrocardiogram (ECG) recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Prostate-specific Antigen (PSA) Doubling From Baseline (in Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With PSA Doubling From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immunoglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resolution of systemic signs and symptoms of snake bite envenomation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of COVID-19 associated pulmonary aspergillosis (CAPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in color of capillary malformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Who Achieved Clinical Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Health Care Utilizations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ropinirole AUC (area under the plasma concentration-time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Borg scale to complete recovery after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PU prevalence (Category 1-4) - change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and extracellular water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual energy X-ray absorptiometry (DEXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Month 6 in CD4+ Naive T Cells (CCR7+ CD45RA+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline to Month 6 in CD4+ Central Memory T Cells (CCR7+CD45RA-CD45RO+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline to Month 6 in Total CD4+ Absolute Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in H.Pylori counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent change from baseline in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: SF 36 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS score for self reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MK0752 systemic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD-RS/ASRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Score of 1 or 2 in CGI-I
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Freedom From Primary Safety Events at 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Treatment Failure at 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Primary Safety Events at 3 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Procedural Success Defined as Electrical Isolation of All PVs
Endpoint domain: Adverse events/effects
Primary endpoint: Shared Decision Making Questionnaire - 9 (SDM Q-9)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experience of Service Questionnaire (ESQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dyadic OPTION scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Point-of-care testing glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lab glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: response to radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Keratometric Tear Break Up Time (KTBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Fluorescein Tear Break Up Time (FTBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: emotional functions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sleep functions
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in overall quality of life (QOL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability of the Question Prompt List
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PUSH tool score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of portacaval pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thromboembolism occurring between day 7-35
Endpoint domain: Adverse events/effects
Primary endpoint: Major bleeding occurring between day 7-35
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Maximal and Minimal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid Extravasation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Transmembrane Pressure (TMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-corrected parasitological cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early urinary continence recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 90-day all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Concentration of Lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Change in Concentration of Mutans Streptococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of preeclampsia/eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: reduction number of tender points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine and fecal recovery of total [14C]-radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastric Emptying of Solids - T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patients visits in a primary health center (PHC) after hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to tolerance of liquids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in radial artery pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the concentration-time curve from 0 to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean voided volume per void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CT Angiography Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients adherent to medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes